Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals International, plc reported a Form 144 notice for the proposed sale of 11,000 Class A ordinary shares to be executed through Charles Schwab & Co., Inc. on 09/03/2025 with an aggregate market value of $383,203.00. The shares were acquired the same day via an employee stock option exercise and the transaction will use a broker payment for a cashless exercise. The filing lists 43,472,928 shares outstanding, and shows prior sales by Michael R. Megna of 15,211 shares on 06/03/2025 (gross proceeds $437,330) and 17,000 shares on 08/04/2025 (gross proceeds $549,936). The filer certifies no undisclosed material adverse information.
Kiniksa Pharmaceuticals International, plc filed a Form 8-K to let investors know it has posted a new investor presentation on its website at investors.kiniksa.com. The company plans to use this presentation, in whole or in part and potentially with modifications, in upcoming meetings with investors, analysts and other audiences.
The investor presentation is furnished as Exhibit 99.1 to this report, with an additional cover page interactive data file listed as Exhibit 104. The filing is informational and does not announce any specific transaction or financial results.
Kiniksa Pharmaceuticals insider transactions by COO Eben Tessari show a mix of purchases and sales executed under a 10b5-1 plan. The reporting person exercised 6,500 vested options at an exercise price of $8.83 on 08/18/2025, acquiring 6,500 Class A ordinary shares. On the same date the reporting person sold 16,100 shares at a weighted-average price of $33.77 and an additional 100 shares at $34.44, reducing beneficial ownership to 40,215 shares. The Form 4 notes the trades were effected pursuant to a 10b5-1 plan executed April 29, 2024, and the option is fully vested and exercisable through 09/16/2029.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 16,200 Class A ordinary shares through Charles Schwab, with an aggregate market value of $547,070, slated for 08/18/2025 on NASDAQ. The filing documents the acquisition history for those shares, including founders' shares from 09/16/2015, two performance award lapses in 03/2022 and 03/2023, and an 08/18/2025 cashless option exercise. The filer, identified by past sales as Eben Tessari at a Lexington, MA address, sold 257,681 shares across seven transactions in May–August 2025, generating total gross proceeds of $8,111,307. The notice includes the seller's representation about lack of undisclosed material adverse information.
Insider transactions by Thomas Malley, a director of Kiniksa Pharmaceuticals International, plc (KNSA) are reported for August 12–14, 2025. The Form 4 shows multiple option exercises and open-market sales. Mr. Malley exercised stock options at strike prices ranging from $1.86 to $15.47, converting options into Class A ordinary shares. The filing reports open-market sales totaling 207,898 shares sold across three days at weighted-average sale prices in the low $30s (individual weighted averages reported at $32.4, $33.32 and $33.09). After these transactions, Mr. Malley directly beneficially owned 12,546 Class A shares and indirectly beneficially owned 71,967 shares through Mossrock Capital, LLC. The filing notes all reported options are fully vested and exercisable and includes broker execution price ranges for the sales.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notifies proposed sales of 78,233 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $2,588,711.00 and an approximate sale date of 08/14/2025 on NASDAQ. The filing states these shares were acquired the same day by employee stock option exercise and disposed via a broker cashless exercise. The filer previously sold 49,407 shares on 08/12/2025 for $1,600,641.00 and 50,129 shares on 08/13/2025 for $1,670,468.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 proposing the sale of 50,129 Class A ordinary shares. The filing shows the shares were acquired and are to be sold on 08/13/2025 via an employee stock option exercise with payment described as Broker Payment for Cashless Exercise. The broker listed is Charles Schwab & Co., Inc. and the aggregate market value is $1,670,468.00. The filing reports 43,472,928 shares outstanding, so the offered block equals about 0.12% of outstanding shares. The document also discloses a sale by Thomas Malley of 49,407 shares on 08/12/2025 for $1,600,641.00. Several identifying fields (CIK/CCC and filer contact/name fields) are not populated in the provided content.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 notifying a proposed sale of 49,407 Class A ordinary shares on 08/12/2025, with an aggregate market value of $1,600,641.00. The shares represent part of the issuer's 43,472,928 outstanding shares and are to be sold on NASDAQ through Charles Schwab & Co., Inc.. The securities were acquired the same day via an employee stock option exercise and settled by a broker payment for cashless exercise. The filer reported "Nothing to Report" for sales in the past three months and included the standard representation that the seller is not aware of undisclosed material adverse information.
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), exercised 29,325 share options at an exercise price of $3.80 and sold 29,325 Class A Ordinary Shares at a weighted average price of $32.55 under a Rule 10b5-1 trading plan. The filing states the option is fully vested and exercisable and reports post-transaction beneficial ownership figures of 86,728 and 57,403 Class A shares, plus 36,542 derivative securities. The sale was executed through a broker-dealer in multiple trades and the filer offers to provide trade-level price details on request.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
